Catalog No.
RHJ69702
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a
Clonality
Monoclonal
Tested applications
IHC: 1:50-1:200
Target
Interleukin-1 homolog 1, IL1H1, IL-1H1, IL-1RP2, IL-1 epsilon, IL1E, IL-1F9, IL36G, IL-1-related protein 2, Interleukin-1 family member 9, IL1RP2, Interleukin-36 gamma, Interleukin-1 epsilon, IL1F9
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NZH8
Applications
IHC
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3X05
An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms., PMID:39848567
Targeting the STAT3/IL-36G signaling pathway can be a promising approach to treat rosacea., PMID:38909883
Secukinumab and Dead Sea Climatotherapy Impact Resolved Psoriasis Skin Differently Potentially Affecting Disease Memory., PMID:38892277
Understanding the impact of risankizumab on keratinocyte-derived IL-23A in a novel organotypic 3D skin model containing IL-23A responsive and IL-17A producing γδ-T-cells., PMID:38284163
Mature IL-36γ Induces Stratum Corneum Exfoliation in Generalized Pustular Psoriasis by Suppressing Corneodesmosin., PMID:37827276
Cathelicidin Antimicrobial Peptide LL37 Induces Toll-Like Receptor 8 and Amplifies IL-36γ and IL-17C in Human Keratinocytes., PMID:36496195
Clinical significance of elevated serum IL-36γ levels in patients with early-stage Hashimoto's thyroiditis., PMID:36470344
TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy., PMID:34797693
IL-36γ and IL-36Ra Reciprocally Regulate NSCLC Progression by Modulating GSH Homeostasis and Oxidative Stress-Induced Cell Death., PMID:34369094
Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?, PMID:33708123
Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses., PMID:32352958
IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema., PMID:31793105
IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment., PMID:30377293
Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation., PMID:30223113
Detection of IL-36γ through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema., PMID:29782895
An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target., PMID:29021166
Altered expression of IL36γ and IL36 receptor (IL1RL2) in the colon of patients with Hirschsprung's disease., PMID:27853811
IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo., PMID:26783184
IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease., PMID:25299544
Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling., PMID:23383400
Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9., PMID:22144259
For research use only. Not for human or drug use.
